menu

Why Bracket?

Science. Technology. Service.

Bracket offers a unique suite of solutions, with a unique perspective on clinical research development. We focus on bringing together best-in-class science, technology and service to drive superior clinical outcome results for our clients and for their patients.

Increasing the Power of Clinical Research Data.

Who We Are

Bracket was created in 2011 through the merger of the Specialty Clinical Services and Clinical Technologies Group business units within United BioSource Corporation (UBC), which was acquired by pharmacy benefit manager Medco Health Solutions. Express Scripts acquired Medco Health Solutions in 2012.

In August 2013, Bracket became an independent portfolio company of Parthenon Capital Partners, a Boston- and San Francisco-based growth-oriented private equity firm that provides capital and strategic resources to growing middle market companies for acquisitions and internal growth. Together, Bracket and Parthenon Capital Partners are committed to continued innovation and growth, and to providing exceptional service to our pharma, biotech and medical device industry clients.

Leadership Team

Being a Leader Requires Experience, Knowledge, and Integrity

Jeff Kinell CEO

Jeff has over 25 years of experience building companies which have developed business models to address inefficiencies in the delivery of healthcare services and drug development processes. He has been a leader in the development of strategic planning processes as well as the development of operating infrastructures for several high growth companies.

Prior to Bracket, Jeff was the CEO of CRI Lifetree until it was acquired by a global CRO. Under his leadership, CRI Lifetree expanded rapidly from a single clinical research unit focusing in one therapeutic area to a leading company providing specialized clinical research services in multiple therapeutic areas. He led the development of three highly differentiated clinical research units and a specialty CRO.

Before joining CRI Lifetree, Jeff was the COO of Comprehensive NeuroScience , a leading provider of Phase I and late stage clinical trials. He led the expansion of CNS’s Phase I capabilities. Jeff was also a founder of Kelson Clinical Trials, a multi-site network conducting pediatric clinical trials. Earlier in his career, he was Executive Vice President and Chief Financial Officer of Mariner Health, a post-acute provider, from start-up through the domestic expansion of the company including its initial public offering.

J. Matthew Bond Chief Financial Officer

Matt brings more than 25 years of experience to Bracket, primarily through leadership positions in growth oriented firms. He is an accomplished executive who champions cultural change and technology solutions to maximize organizational performance. Matt has a proven ability to analyze operations, organizational challenges, and growth opportunities, then develop and implement strategic and tactical solutions that drive the enterprise to the next level of success.

Most recently, Matt co-founded and served as the CFO of Aptiv Solutions, a mid-size, specialized contract research organization focused on adaptive methods for biopharmaceutical clinical development and in the medical device approval market. During his tenure, the business grew from its startup phase to a large multi-national organization primarily through a series of strategic acquisitions, and was the recognized leader in the development and execution of adaptive clinical trials until its acquisition in 2014. Previously, Matt was Executive Vice President and CFO of a global, growth oriented CRO, where over 6 years he led a very successful initial public offering and created significant value for the various stakeholders.

Earlier in his career, he was a vice president with Marriott International’s senior living business and spent a number of years with Arthur Andersen. He is a graduate of Wake Forest University and is a CPA (inactive).

David G. Daniel, MD Sr. Vice President and Chief Medical Officer

Clinical Professor of Psychiatry, George Washington University

Dr. Daniel provides overall scientific, clinical and strategic direction for Bracket’s services.

Dr. Daniel was the founder and President of Global Learning, LLC which was acquired by United BioSource Corporation in July 2006. He formerly served as Medical Director of the NIMH Neuroscience Center at Saint Elizabeth’s, Director of Clinical Trials for the Stanley Foundation, and was a founding Principal of Best Practice, LLC.

For over 20 years, Dr. Daniel has supervised and trained raters in psychiatric clinical trials in the US and globally. He has published numerous scientific articles involving clinical trials and investigations of the psychopathology of mental illness. He has received patent protection for new treatment approaches in epilepsy, anxiety disorders and psychotic disorders.

Dr. Daniel graduated Phi Beta Kappa and Magna Cum Laude from Emory University and obtained his medical school and psychiatry post-graduate training at Vanderbilt University, where he served as chief resident. He was a medical staff fellow and senior staff fellow within the intramural program of the National Institute of Mental Health (DIRP, NIMH) for five years.

Jim Primerano Sr. Vice President and General Manager, eClinical

Jim leads the eClinical division of Bracket.  As Sr. Vice President and General Manager, he oversees all aspects of the eClinical solutions portfolio. With 15 years of clinical research and technology experience, he and his team bring innovative solutions to advance clients’ clinical objectives.  Prior to joining Bracket, Jim was Sr. Director of Product Strategy with Medidata Solutions, where he was responsible for market analysis to drive portfolio expansion.

Jim holds a BA in Biology from the University of Pennsylvania and an MBA in Global Business from Rider University.

Adam Butler Sr. Vice President, Strategic Development and Corporate Marketing

Adam is responsible for strategic development and marketing activities for Bracket’s service offerings in Randomization and Trial Supply Management, Electronic Clinical Outcome Assessments, and Rater Training and Quality Assurance services. Adam has 12 years of experience working in the pharmaceutical services industry. Prior to his work with Bracket he worked in enterprise software development for firms including Hewlett-Packard, Bluestone Software, and Fahrenheit 450.

Colin Bower Vice President, Scientific Services

Colin brings extensive business consulting and senior executive experience, having managed and driven substantial growth of public and private companies on a global scale. Colin led Arthur Andersen’s multi-million dollar global capital markets practice, providing advisory, strategy and transaction services to multinational clients and sovereign entities across EMEA and APAC.

Prior to joining Andersen, Colin was a US Presidential Appointee at the US Department of the Treasury. Upon leaving Andersen, Colin successfully managed and grew high growth companies to capital events, and was the founder and general partner of a private equity fund.

Colin has a BA from McGill University, an MBA from the University of Chicago Booth School of Business, and a Certificate in Advanced Corporate Finance from INSEAD, France.

Stephane Deleger Vice President, Sales – eClinical

Stephane is the Executive Director, Account Management at Bracket. In his current role, he is responsible for the global sales of Bracket service offerings in Randomization and Trial Supply Management and Electronic Clinical Outcome Assessments. Stephane has been working in the healthcare industry for over 15 years, when he started his career as a biostatistician working for CROs and sponsors. Prior to joining Bracket, Stephane was an eClinical Sales Manager, and also worked as an Epidemiologist for the Public Health Institute in Berkeley, California.

Stephane holds a Master’s Degree in Cellular Biology and a Post Graduate Degree in Biomathematics from the University of Pierre et Marie Curie, Paris, France.

Jason Henson Vice President, Finance

Jason leads all finance and accounting functions for Bracket. He has more than 20 years of experience in finance and financial planning roles. Prior to Bracket, Jason was Vice President of Finance at Ricoh Americas Corporation, a global technology and document management solutions provider based in Malvern, PA. Jason received his BS in Accounting from Wake Forest University.

Jason West Vice President, Product Innovation

Jason has been with Bracket for 13 years, where he oversaw Software Development, IT and Client Support for over ten years. Jason leads Bracket’s Product Innovation organization, and is responsible for defining and driving the development and implementation of the Bracket Product Roadmap, which ensures that technology investments and resources support Bracket’s strategic direction.

Jason received a Bachelor of Science degree in Computer Engineering from California Polytechnic State University, San Luis Obispo. He is also a Microsoft Certified Professional.

Thomas Barlow Associate Vice President, Total Quality Management

Thomas is responsible for all of Bracket’s Quality Management Systems. Thomas has over 15 years of Quality Management experience. Prior to Bracket, he was Manager Quality Services for Clarix LLC and Quatern, LLC and the Audit Manager for Almac Clinical Technologies. Thomas holds a BS in Biology from Millersville University and has formalized training in Good Clinical Practices (GCP), Good Manufacturing Practices (GMP), 21 CFR 11, FDA, ICH and IEEE Validation Guidelines, HIPAA, CAPA Management, Deviation / Incident Reporting and Project Management.

Scientific Leadership

Bracket's Subject Matter Experts… Ahead in Every Aspect

David G. Daniel, MD Sr. Vice President and Chief Medical Officer

Clinical Professor of Psychiatry, George Washington University

Dr. Daniel provides overall scientific, clinical and strategic direction for Bracket’s services.

Dr. Daniel was the founder and President of Global Learning, LLC which was acquired by United BioSource Corporation in July 2006. He formerly served as Medical Director of the NIMH Neuroscience Center at Saint Elizabeth’s, Director of Clinical Trials for the Stanley Foundation, and was a founding Principal of Best Practice, LLC.

For over 20 years, Dr. Daniel has supervised and trained raters in psychiatric clinical trials in the US and globally. He has published numerous scientific articles involving clinical trials and investigations of the psychopathology of mental illness. He has received patent protection for new treatment approaches in epilepsy, anxiety disorders and psychotic disorders.

Dr. Daniel graduated Phi Beta Kappa and Magna Cum Laude from Emory University and obtained his medical school and psychiatry post-graduate training at Vanderbilt University, where he served as chief resident. He was a medical staff fellow and senior staff fellow within the intramural program of the National Institute of Mental Health (DIRP, NIMH) for five years.

Steve Targum, MD Scientific Director

Dr. Targum consults widely to the pharmaceutical industry regarding the design and implementation of clinical trials for new psychotropic drugs and the progression of drug development from concept to approval to launch. In addition to his work at Bracket, Dr. Targum is a Chief Medical Advisor at Prana Biotechnology Ltd. and has served as Chief Medical Officer at several small biotechnology and pharmaceutical companies.

In 1991, Dr. Targum established and operated a multi-site clinical trials program in Philadelphia. As Principal Investigator, he conducted over 200 clinical drug trials in therapeutic areas that included anxiety, depression, mania, schizophrenia, and Alzheimer’s disease.

In 2001, Dr. Targum founded PharmaStar, a rater training and medical education company focused on CNS drug development and international clinical trials. The company grew quickly and became the global leader in this niche when it was sold in October 2004 to United BioSource Corporation.

Previously, He was Professor of Psychiatry and Vice-Chairman of the Department of Mental Health Sciences at Hahnemann University School of Medicine (Philadelphia) from 1989-1995. He has published over 100 scientific articles in the areas of psychopharmacology, psychobiology, and clinical trials methodology.

Dr. Targum has a B.A. in biology from Colgate University and an M.D. from Mount Sinai School of Medicine.

Joan Busner, Ph.D. Clinical Vice President

Clinical Associate Professor of Psychiatry, Penn State College of Medicine

Dr. Busner has over 25 years of experience as an academic clinical psychiatric researcher. She has served as the Principal Investigator for 49 industry-sponsored psychiatric clinical trials and Sub-Investigator for 35 additional clinical trials. She has served continuously on Institutional Review Boards (IRBs) for the 20 years that preceded her move to Bracket. Dr. Busner has held medical school faculty appointments since 1985 and is currently the Clinical Associate Professor of Psychiatry at Penn State College of Medicine.

Dr. Busner is an active contributor to psychopharmacology literature and has authored or coauthored over 100 peer-reviewed articles and national or international scientific presentations. She serves as Bracket’s Expert Presenter and Scientific Lead for US and multinational studies of depressive disorders, anxiety disorders, attention deficit hyperactivity disorder and all child and adolescent psychiatric indications.

She has trained thousands of psychiatric clinical trial investigators across the globe and lectures frequently on the application of objective rating scales in the assessment of diagnosis and efficacy in psychopharmacology, ethics in psychiatric research, the placebo effect in psychiatric research and techniques for its minimization, the role of IRBs and clinical trial methodology.

Dr. Busner received her PhD in Experimental Social Psychology and her MA in General Psychology from Adelphi University. She is licensed to practice psychology in Pennsylvania, Missouri and New York.

Scott Hamilton, PhD Principal Biostatistician

Adjunct Professor, Stanford University School of Medicine, Dept. of Neurology and Neurological Sciences

Dr. Hamilton was President and Founder of DynaRand, LLC, a software company that pioneered the development of IVRS and IWRS solutions for clinical trials management. DynaRand was acquired by United BioSource Corporation in 2005. Since the inception of DynaRand in 1998, he has pioneered the use of IVRS for automated adaptive studies, especially in the area of dynamic randomization. Dr. Hamilton works closely with pharmaceutical companies regarding the statistical aspects of adaptive trials and randomization algorithms, in addition to monitoring the integrity of Bracket’s randomization processes.

Previously, Dr. Hamilton held a role of Senior Biostatistician at Genentech, Inc. and is a NI-NINDS Grant Review Committee member. Widely published, he holds memberships in the American Statistical Association and the American Academy of Neurology and Biometrics.

Dr. Hamilton received his undergraduate degree from the University of California at Davis in Economics and Rhetoric, his Master of Science from the University of California at Los Angeles in Biostatistics, and his PhD in Biostatistics from the University of North Carolina.

Alan Kott, MUDr Clinical Vice President and Practice Lead, Data Analytics

Dr. Kott is based in Bracket’s Prague office and until recently was Senior Clinical Manager for Europe. Having led the development of the Data Analytics Program for Bracket, he has overseen the design and reporting of data analytics in multiple large schizophrenia studies. For the past seven years, he has also provided training to investigators as an Expert Trainer.

Dr. Kott has been responsible for the design and implementation of multiple in-study data quality programs and served as a Product Business Owner for Rater Reliability Statistical Measures Application. Prior to Bracket, Dr. Kott worked as a house officer in Psychiatry at General Teaching Hospital, Department of Psychiatry, and as an Assistant Professor at Charles University, 1st Medical Faculty – Department of Psychiatry, in Prague. Dr. Kott has a Medicinae Universae Doctor (MUDr) from Charles University.

David S. Miller, MD, MA Clinical Vice President

Dr. Miller has over 20 years of clinical, clinical research and teaching experience, primarily in the field of geriatric psychiatry. After completing his 2-year fellowship in geriatric psychiatry at the University of Pennsylvania, he joined the faculty and served as an Assistant Professor of Psychiatry. Dr. Miller then went on to the University of Medicine and Dentistry of New Jersey, where he served as an Associate Professor of Psychiatry.

Prior to joining Bracket, Dr. Miller served as Chief of Geriatric Psychiatry, Medical Director of ECT, and President of the Medical Staff at Friends Hospital in Philadelphia, PA. At all of these institutions, he oversaw the education and training of medical students, residents and fellows in geriatric psychiatry, and was recognized with a departmental teaching award.  Dr. Miller has served as a Principal Investigator in a number of dementia clinical trials. In addition, he has lectured locally, nationally and internationally on his dementia related research.

Dr. Miller serves as the Co-Chair of the ISTAART funded Neuropsychiatric Syndromes in Dementia – Professional Interest Area (NPS-PIA), and as the Co-Chair of the ISCTM Working Group focusing on the same area. Additionally, Dr. Miller is a co-author on the updated ADCS ADAS-Cog administration and scoring manual.

Since joining Bracket, Dr. Miller has consulted on multiple dementia protocols and has served as the Expert Presenter at dozens of investigators’ meetings across the globe, including those addressing behavioral abnormalities and agitation in the context of dementia.

Gary Sachs, MD Clinical Vice President

Associate Professor of Psychiatry, Harvard Medical School

Dr. Sachs is the Therapeutic Area Leader in bipolar disease and mood disorders at Bracket. He previously co-founded Concordant Rater Systems, a specialty provider of technologies to improve CNS clinical research. Dr. Sachs is a recognized expert clinical trialist with extensive experience in rater training and the methodologies of mood and anxiety disorder research. He has been instrumental in developing technology-based solutions for randomized controlled trials that identify correlates of high placebo response, improve signal detection and reduce the risk of failed trials.

Dr. Sachs is the founder and director of the Bipolar Clinic and Research Program at Massachusetts General Hospital (MGH) and is an Associate Professor of Psychiatry at Harvard Medical School. After graduating from the University of Pennsylvania and the University of Maryland Medical School, he completed his residency at MGH. His areas of academic interest include psychopharmacology, chronobiology, bipolar mood disorder and development of pragmatic measure-based practice guidelines.

Dr. Sachs is Chair of the National Alliance on Mental Illness Scientific Advisory Board and serves on the Scientific Advisory Board of the Depression and Bipolar Support Alliance. He has authored over 200 articles, abstracts, books and book chapters.

X